Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas

Annals of Hematology

Volumn 91, Issue 11, 2012, Pages 1741-1745

  Lin, Tung Liang ^a   Kuo, Ming Chung ^a   Shih, Lee Yung ^a,b   Dunn, Po ^a   Wang, Po Nan ^a   Wu, Jin Hou ^a   Tang, Tzung Chih ^a   Chang, Hung ^a   Hung, Yu Shin ^a   Lu, Shu Chen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Diffuse large B cell lymphoma; Follicular lymphoma; Follow up; Image; Relapse; Surveillance computed tomography

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; FEMALE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HUMAN; IMAGE ANALYSIS; LARGE CELL LYMPHOMA; LYMPH NODE ENLARGEMENT; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PHARYNX DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN TUMOR; SOFT TISSUE TUMOR;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAIWAN; TOMOGRAPHY, X-RAY COMPUTED; VINCRISTINE;

EID: 84867337210     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1508-0     Document Type: Article

References (20)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
2. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
3. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732
4. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferme C, Tilly H (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045
5. Seshadri T, Kuruvilla J, Crump M, Keating A (2008) Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant 14:259-267
6. Moskowitz CH, Nimer SD, Glassman JR, Portlock CS, Yahalom J, Straus DJ, O'Brien JP, Elkin N, Bertino JR, Zelenetz AD (1999) The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant 23:561-567
7. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, Hagenbeek A, Somers R, Chauvin F, Philip T (1998) The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group Blood 92:3562-3568
8. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Briere J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190
9. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD (2006) Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 17:909-913
10. Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O (2011) The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol 90:165-171
11. Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Lacasce AS (2012) High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma 53:1113-1116
12. Weeks JC, Yeap BY, Canellos GP, Shipp MA (1991) Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 9:1196-1203
13. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253
14. Guppy AE, Tebbutt NC, Norman A, Cunningham D (2003) The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 44:123-125
15. Elis A, Blickstein D, Klein O, Eliav-Ronen R, Manor Y, Lishner M (2002) Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. Am J Hematol 69:41-44
16. Van Den Bossche B, Lambert B, De Winter F, Kolindou A, Dierckx RA, Noens L, Van DeWiele C (2002) 18FDG PET versus high-dose 67 Ga scintigraphy for restaging and treatment followup of lymphoma patients. Nucl Med Commun 23:1079-1083
17. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ (2002) Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 94:879-888
18. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD (2005) Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652-4661
19. Thompson CA, Charlson ME, Schenkein E, Wells MT, Furman RR, Elstrom R, Ruan J, Martin P, Leonard JP (2010) Surveillance CT scans are a source of anxiety and fear of recurrence in longterm lymphoma survivors. Ann Oncol 21:2262-2266
20. Armitage JO, Loberiza FR (2006) Is there a place for routine imaging for patients in complete remission from aggressive lymphoma? Ann Oncol 17:883-884